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The article Dutch Economic Value of Radium-223 in
Metastatic Castration-Resistant Prostate Cancer, written by
Michel L. Peters, Claudine de Meijer, Dirk Wyndaele,
Walter Noordzij, Annemarie M. Leliveld-Kors, Joan van
den Bosch, Pieter H. van den Berg, Agni Baka, Jennifer G.
Gaultney was originally published electronically on the
publisher’s internet portal (currently SpringerLink) on 2nd
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to  The Author(s) 2017 and the article is forthwith dis-
tributed under the terms of the Creative Commons Attri-
bution-NonCommercial 4.0 International License (http://
creativecommons.org/licenses/by-nc/4.0/), which permits
any noncommercial use, duplication, adaptation, distribu-
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source, a link is provided to the Creative Commons license
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